Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for...

Area of Science:

• Nephrology
• Hematology
• Immunology

Background:

• Thrombotic microangiopathies (TMAs) are a group of disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ damage.
• ADAMTS13 deficiency, either inherited or acquired, is a primary cause of TMAs.
• Acquired ADAMTS13 deficiency is often mediated by autoantibodies, with drug-induced cases being recognized.

Observation:

• A 52-year-old male with multiple sclerosis developed severe renal failure secondary to TMA.
• The TMA was attributed to severe ADAMTS13 deficiency caused by an IgG antibody that emerged after interferon-beta therapy.
• This represents a rare instance of interferon-beta-induced TMA linked to acquired ADAMTS13 deficiency.

Findings:

• The patient was treated with interferon-beta discontinuation, plasma exchange, corticosteroids, and hemodialysis.
• Despite initial hematologic improvement, a relapse of hemolysis occurred.
• Introduction of rituximab led to a durable hematologic recovery.

Implications:

• This case highlights a potential adverse effect of interferon-beta treatment, specifically the induction of TMA via acquired ADAMTS13 deficiency.
• It underscores the importance of considering drug-induced TMAs in patients presenting with relevant clinical symptoms.
• The successful use of rituximab in this scenario suggests its potential efficacy in managing interferon-beta-induced TMA due to ADAMTS13 deficiency.